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Conclusions
Introduction
POLYNUCLEOTIDE KINASE/PHOSPHATASE (PNKP) is an enzyme that plays 
an essential role in various DNA strand-break repair pathways, such as 
single-strand break repair (SSBR), nonhomologous end-joining (NHEJ) and 
base-excision repair (BER).1 After DNA is damaged by agents such as 
reactive oxygen species, ionizing radiation or mutagenic chemicals,
the backbone may break, leaving incorrect functional groups on what are 
normally the 5′-phosphate or 3′-hydroxyl termini. PNKP repairs
this damage before the backbone is ligated again, by restoring the ends
to their proper terminal groups using the enzyme’s bifunctional
5′-kinase and 3′-phosphatase activities.
Mutations that disrupt the catalytic activity of PNKP give rise to neurological 
diseases, such as microcephaly with seizures (MCSZ) and ataxia with 
oculomotor apraxia 4 (AOA4).2 Because it is a DNA repair enzyme, PNKP is 
being investigated as a potential drug target of sensitizing agents for 
chemotherapy and radiation therapy in cancer treatment.3
C. elegans PNKP (CePNKP) is a useful model for studying human PNKP 
(hPNKP), but, intriguingly, CePNKP shows a more exclusive preference for 
DNA substrates with recessed 5′-hydroxyl ends than hPNKP. Notably,
the kinase domain of mammalian PNKP (mPNKP) prefers phosphorylating 
DNA substrates with recessed 5′-hydroxyl ends over DNA substrates with 
blunt ends.4
To elucidate the reason for the unique substrate specificity of CePNKP, the 
structure of CePNKP in complex with its DNA substrate must be determined 
in atomistic detail by molecular modelling. The generated structural model 
is compared with our experimental results of kinase activity assays of 
CePNKP.
Experimental Section
Wild-type CePNKP (WT Ce), and a mutant for each surface (Fig. 1) with 
amino-acid substitutions in positions likely to be binding sites for the DNA 
molecule were analyzed. 
Quantification of proteins. In order find and compare the concentrations of 
protein in the stock solutions, the A280 assay was applied to measure
the absorbances of 2 μL drops of each protein solution. This data was used
to determine protein concentrations by the Warburg–Christian method.
Then, each protein stock solution was diluted to the same concentration of 
18.20 mg/mL. This was done to ensure that the results of
the kinase activity assay could be comparable.
Kinase activity assay. Each 18.20 mg/mL protein solution was serially diluted 
with dilution factors of 1, 2, 4, 8, 16, 32, 64. Equal amounts of substrate 
(oligo DNA and ATP) were added to each diluted protein solution.
The solutions were incubated at 16 °C for 30 minutes. Then, the reactions 
were stopped with a urea loading buffer. The solutions were subjected to 
denaturing polyacrylamide gel electrophoresis (PAGE) to qualitatively assess 
the catalytic activity of each wild-type and mutant CePNKP on 5′-OH groups 
at the recessed and blunt ends of DNA. 
Computational Section
• The protein quantification and kinase assays will be repeated to tune up the experimental conditions
that drive the phosphorylation reaction forward.
• 3D structural models for each CePNKP and oligo DNA were generated by MD simulations.
• Typical conformations and regions of flexibility in the binding sites of the structural models of
CePNKP and oligo DNA were identified.
• The oligo DNA in complex with CePNKP will be generated by docking the structural models
generated in this work. The complex will be studied by MD simulations.
• In silico mutagenesis will be performed in the structural model of the complex
to gain insight into the binding of CePNKP with its DNA substrate.
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Figure 4. Typical oligo-DNA conformations from the MD simulation over 68.72 ns.
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Figure 1. The three DNA-binding surfaces on PNKP. Amino-acid site mutations
that disrupt the binding of DNA to PNKP are listed for each surface.5
Figure 5. Ribbon representations of three-dimensional structures of PNKP.
Side chains of catalytic and mutated (Fig. 1) residues depicted in stick representation. 
Left: CePNKP structure at  t  = 2.80 ns  from the MD simulation over 6.12 ns.
Right: mPNKP in complex with oligo DNA from crystallographic data (PDB: 3ZVN).
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For CePNKP, the protein sequence is available, but its 3D structure has not been determined 
experimentally. Hence, we performed homology modelling to thread the CePNKP sequence
into the mouse PNKP fold found by X-ray crystallography.
Homology modelling. MODELLER 9.17 software6 was used to create a 3D structural model of 
CePNKP using mouse PNKP as a template. The procedure for this is summarized in Fig. 3:
Figure 3. Flowchart of the homology modelling procedure. 
GROMACS 2016.1 software7 was used to set up structural models for solutions and to perform 
MD simulations with the force field AMBER94 for nucleic acids and AMBER99 for proteins.
Model of Oligo-DNA in solution: The ideal 3D structure of B-DNA was the starting geometry for 
the oligo-DNA substrate. The oligo DNA was placed into a box of water
(8.09 nm × 5.11 nm × 5.16 nm) containing 0.15 M NaCl ions. 
Model of CePNKP in solution: The 3D homology model was the starting geometry for
the CePNKP enzyme. The enzyme was placed into a box of water
(10.25 nm × 6.78 nm × 6.69 nm) containing 0.15 M NaCl ions.
Molecular Dynamics simulations. Each solution was sequentially subjected to:
(1st) energy minimization, (2nd) NVT equilibration,
(3rd) NPT equilibration for energy relaxation, and (4th) NPT equilibration to produce
the trajectory each molecule’s motion in water at 1 atm and 300 K over time.
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